Disease Detail

ID DOID:9952
Name acute lymphocytic leukemia
Definition A lymphoblastic leukemia that is characterized by over production of lymphoblasts.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphocytic leukemia acute lymphocytic leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown ABT-348 acute lymphocytic leukemia not applicable detail...
Unknown unknown BMS-754807 acute lymphocytic leukemia no benefit detail...
Unknown unknown AS605240 + Prednisolone acute lymphocytic leukemia not applicable detail...
ETV6-RUNX1 N/A acute lymphocytic leukemia not applicable detail...
IKZF1 del N/A acute lymphocytic leukemia not applicable detail...
NRAS mut CDKN2A mut Trametinib acute lymphocytic leukemia resistant detail...
NOTCH1 act mut Brontictuzumab acute lymphocytic leukemia sensitive detail...
Unknown unknown Natalizumab acute lymphocytic leukemia not applicable detail...
ETV6 inact mut N/A acute lymphocytic leukemia not applicable detail...
KMT2A-AFF1 AZD5153 acute lymphocytic leukemia predicted - sensitive detail...
Unknown unknown AS605240 acute lymphocytic leukemia not applicable detail...
Unknown unknown AS605240 + Dexamethasone acute lymphocytic leukemia not applicable detail...
KMT2A rearrange Cytarabine + Panobinostat acute lymphocytic leukemia sensitive detail...
KMT2A rearrange Cytarabine + Mocetinostat acute lymphocytic leukemia sensitive detail...
KMT2A rearrange Cytarabine + Dacinostat acute lymphocytic leukemia sensitive detail...
KMT2A rearrange Cytarabine + Romidepsin acute lymphocytic leukemia sensitive detail...
KMT2A rearrange Romidepsin acute lymphocytic leukemia decreased response detail...
KMT2A rearrange Cytarabine acute lymphocytic leukemia sensitive detail...
Unknown unknown T-3775440 acute lymphocytic leukemia no benefit detail...
PTEN loss BGT226 acute lymphocytic leukemia sensitive detail...
Unknown unknown KPT-8602 acute lymphocytic leukemia not applicable detail...
Unknown unknown TAS4464 acute lymphocytic leukemia not applicable detail...
Unknown unknown TG02 acute lymphocytic leukemia not applicable detail...
Unknown unknown Blinatumomab acute lymphocytic leukemia not applicable detail...
Unknown unknown JQ1 + Silmitasertib acute lymphocytic leukemia not applicable detail...
Unknown unknown Prexasertib acute lymphocytic leukemia not applicable detail...
Unknown unknown ORY-1001 acute lymphocytic leukemia not applicable detail...
Unknown unknown OBI-3424 acute lymphocytic leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed
NCT00549848 Phase III Daunorubicin + Pegaspargase + Vincristine Cytarabine Mercaptopurine Thioguanine Clofarabine + Cyclophosphamide + Etoposide Methotrexate Dasatinib Doxorubicin Dexamethasone Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Active, not recruiting
NCT00550992 Phase I Busulfan Melphalan Mercaptopurine Cytarabine + Etoposide + Mitoxantrone Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Thioguanine Cyclosporine anti-thymocyte globulin Daunorubicin Leucovorin Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia Unknown status
NCT00679536 Phase Ib/II anti-thymocyte globulin + Busulfan + Fludarabine Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Unknown status
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed
NCT00866281 Phase Ib/II Midostaurin A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia Terminated
NCT00908167 Phase I Clofarabine + Cytarabine + Sorafenib Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies Completed
NCT00990249 Phase II anti-thymocyte globulin + Busulfan + Clofarabine Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed
NCT01077544 Phase I Nilotinib A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) Completed
NCT01162551 Phase II Methotrexate + Sirolimus Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma Completed
NCT01187810 Phase I Fenretinide Cytarabine Methotrexate Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL Unknown status
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting
NCT01256398 Phase II Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Active, not recruiting
NCT01266083 Phase II WT1 vaccine Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed
NCT01319981 Phase II Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Cyclophosphamide Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Active, not recruiting
NCT01321346 Phase I Cytarabine Panobinostat A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed
NCT01324180 Phase I Metformin Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) Completed
NCT01338987 Phase II Tacrolimus Methotrexate Leuprolide Cyclophosphamide Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation Active, not recruiting
NCT01371630 Phase Ib/II inotuzumab ozogamicin Cyclophosphamide + Cytarabine + inotuzumab ozogamicin + Methotrexate + Vincristine Mercaptopurine + Methotrexate + Prednisone + Vincristine Rituximab Cytarabine + inotuzumab ozogamicin + Methotrexate Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia Recruiting
NCT01424982 Phase II Pegfilgrastim Cytarabine + Methotrexate + Ponatinib Ponatinib + Vincristine Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Leucovorin Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT01483690 Phase Ib/II Pegaspargase Methotrexate Dexamethasone Vincristine Decitabine Mitoxantrone A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Terminated
NCT01523977 Phase I Prednisone Everolimus Vincristine Doxorubicin Pegaspargase Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL Completed
NCT01614197 Phase I Etoposide Cyclophosphamide Prednisone Cytarabine Temsirolimus Methotrexate A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Recruiting
NCT01620216 Phase II Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients Recruiting
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated
NCT01634217 Phase I Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Completed
NCT01658007 Phase I Sirolimus Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma Terminated
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting
NCT01744223 Phase Ib/II Rimiducid BPX-501 Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Recruiting
NCT01769209 Phase II Bortezomib Cytarabine + Methotrexate Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated
NCT01841333 Phase II Glasdegib PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant Recruiting
NCT01885689 Phase II Clofarabine + Melphalan Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission Active, not recruiting
NCT01885897 Phase Ib/II ALT-803 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Active, not recruiting
NCT01925131 Phase I Cyclophosphamide + Prednisone + Vincristine inotuzumab ozogamicin S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Recruiting
NCT01943682 Phase I CPX-351 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Active, not recruiting
NCT02003222 Phase III Cytarabine Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Mercaptopurine + Methotrexate + Prednisone + Vincristine Cyclophosphamide + Cytarabine + Mercaptopurine + Pegaspargase Methotrexate + Pegaspargase Cytarabine + Etoposide + Methotrexate Rituximab Blinatumomab Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Recruiting
NCT02043587 Phase II Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Etoposide Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Active, not recruiting
NCT02071927 Phase I CB-839 Study of the Glutaminase Inhibitor CB-839 in Leukemia Completed
NCT02083250 Phase I anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Active, not recruiting
NCT02089230 Phase Ib/II Binimetinib MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Active, not recruiting
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting
NCT02101853 Phase III Blinatumomab Leucovorin + Pegaspargase + Vincristine Mercaptopurine + Thioguanine Asparaginase + Cyclophosphamide + Etoposide Cytarabine + Dexamethasone + Methotrexate Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Recruiting
NCT02129062 Phase II Ibrutinib Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Terminated
NCT02141828 Phase I Pinometostat A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed
NCT02143635 Phase I HDM201 Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt Active, not recruiting
NCT02146924 Phase I Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia Recruiting
NCT02158858 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms Recruiting
NCT02181478 Phase I Fludarabine Cyclophosphamide Intra-Osseous Co-Transplant of UCB and hMSC Recruiting
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed
NCT02269579 Phase II CPX-351 Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment Withdrawn
NCT02311998 Phase Ib/II Bosutinib + inotuzumab ozogamicin Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Recruiting
NCT02319369 Phase I DS-3032b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies Recruiting
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting
NCT02420717 Phase II Ruxolitinib Cytarabine + Methotrexate Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Dasatinib Mercaptopurine + Methotrexate + Prednisone + Vincristine Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated
NCT02484430 Phase II Sapanisertib TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Active, not recruiting
NCT02487459 Phase I BPX-501 Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn
NCT02518750 Phase II Bortezomib + Dexamethasone + Panobinostat Pegaspargase Mercaptopurine Nelarabine Mitoxantrone Vincristine Cyclophosphamide + Etoposide Cytarabine + Methotrexate + Prednisone Clofarabine Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated
NCT02535806 Phase II Vincristine Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults Terminated
NCT02538926 Phase II Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Asparaginase Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Withdrawn
NCT02553460 Phase II Cyclophosphamide Mitoxantrone Dexamethasone Bortezomib Etoposide Vincristine Pegaspargase Vorinostat Cytarabine Methotrexate Leucovorin Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I Recruiting
NCT02614066 Phase Ib/II KTE-C19 A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3) Recruiting
NCT02625480 Phase Ib/II KTE-C19 A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4) Recruiting
NCT02629692 Phase Ib/II K0706 Safety, Tolerability, Pharmacokinetics and Activity of K0706 Recruiting
NCT02723994 Phase II Prednisone Dexamethasone + Doxorubicin Leucovorin Mercaptopurine + Thioguanine Asparaginase + Cytarabine Ruxolitinib Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Recruiting
NCT02746952 Phase I UCART19 Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM) Recruiting
NCT02767934 Phase II Pembrolizumab Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Recruiting
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Active, not recruiting
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Recruiting
NCT02815059 Phase I Dasatinib + Ibrutinib + Prednisone Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone Withdrawn
NCT02819804 Phase I Dasatinib + Nivolumab Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Active, not recruiting
NCT02861040 Phase I Vincristine + Volasertib Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Withdrawn
NCT02879695 Phase I Blinatumomab + Ipilimumab + Nivolumab Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Recruiting
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Recruiting
NCT02906371 Phase I Tocilizumab Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome Active, not recruiting
NCT02930109 Phase Ib/II Cytarabine + Triciribine A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Recruiting
NCT02935543 Phase II CART19 cells CART19 in Patient With ALL Terminated
NCT02997761 Phase II Blinatumomab + Ibrutinib Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Recruiting
NCT03007147 Phase III Pegaspargase Methotrexate Leucovorin Cytarabine Mercaptopurine Thioguanine Vincristine Cyclophosphamide Imatinib Ifosfamide Dexrazoxane Daunorubicin Dexamethasone Methylprednisolone Etoposide Prednisolone Doxorubicin Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting
NCT03016377 Phase I Anti-CD19 CAR T cells Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting
NCT03020030 Phase III Nelarabine Dexrazoxane Asparaginase Vincristine Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting
NCT03023046 Phase II Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting
NCT03056339 Phase Ib/II Cyclophosphamide + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Recruiting
NCT03069469 Phase I DCC-3014 Study of DCC-3014 in Patients With Advanced Malignancies Recruiting
NCT03071276 Phase II Cytarabine + Fludarabine + Methotrexate + Prednisone + Selinexor Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia Recruiting
NCT03094611 Phase II inotuzumab ozogamicin Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia Active, not recruiting
NCT03104491 Phase Ib/II inotuzumab ozogamicin Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia Suspended
NCT03110354 Phase I DS-3201b DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) Recruiting
NCT03117751 Phase II Cyclophosphamide Vincristine Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting
NCT03128034 Phase Ib/II Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Recruiting
NCT03132454 Phase I Decitabine + Palbociclib Dexamethasone + Palbociclib Palbociclib Palbociclib + Sorafenib Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias Recruiting
NCT03147612 Phase II Mesna Vincristine Dexamethasone Rituximab Filgrastim Ponatinib Cyclophosphamide Methotrexate Cytarabine Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT03150693 Phase III Rituximab Doxorubicin Mercaptopurine Methotrexate Cyclophosphamide + Cytarabine Thioguanine Allopurinol Daunorubicin Dexamethasone Vincristine inotuzumab ozogamicin Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Recruiting
NCT03160079 Phase Ib/II Blinatumomab + Pembrolizumab Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts Recruiting
NCT03181126 Phase I Navitoclax + Venetoclax A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia Recruiting
NCT03263572 Phase II Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib Blinatumomab + Dexamethasone + Ponatinib Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT03267186 Phase II Ibrutinib Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Recruiting
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Recruiting
NCT03319901 Phase I Cytarabine Mercaptopurine Methotrexate Cyclophosphamide Venetoclax Doxorubicin Etoposide Vincristine Venetoclax and Chemotherapy In ALL Recruiting
NCT03349281 Phase I Dexamethasone + Doxorubicin + MLN4924 + Pegaspargase + Vincristine Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia Recruiting
NCT03386513 Phase I IMGN632 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting
NCT03414450 Phase I Dasatinib + ETC-1907206 Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies Withdrawn
NCT03472573 Phase I Dexamethasone + Palbociclib Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Recruiting
NCT03488225 Phase II Mercaptopurine + Methotrexate + Prednisone + Vincristine Cytarabine + Leucovorin + Methotrexate inotuzumab ozogamicin Ofatumumab Rituximab Cytarabine + Doxorubicin + Methotrexate + Vincristine Pegfilgrastim Cyclophosphamide + Dexamethasone + Mesna Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia Active, not recruiting
NCT03504644 Phase Ib/II Venetoclax + Vincristine Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Recruiting
NCT03512405 Phase Ib/II Blinatumomab + Pembrolizumab Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia Recruiting
NCT03515200 Phase I Cytarabine + Dexamethasone + Methotrexate Bortezomib + Dasatinib + Dexamethasone + Doxorubicin + Palbociclib Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia Recruiting
NCT03571321 Phase I Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Rituximab Doxorubicin Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Not yet recruiting
NCT03575325 Phase II CPX-351 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Recruiting
NCT03576547 Phase Ib/II Cytarabine + Dexamethasone + Methotrexate + Ponatinib + Rituximab + Venetoclax Ponatinib + Venetoclax for Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) Recruiting
NCT03589326 Phase III Cytarabine + Methotrexate + Ponatinib Dexamethasone + Ponatinib + Vincristine Ponatinib + Prednisone + Vincristine Dexamethasone + Imatinib + Vincristine Cytarabine + Imatinib + Methotrexate Imatinib + Prednisone + Vincristine An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Recruiting
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Recruiting
NCT03698552 Phase Ib/II ADCT-602 ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Recruiting
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting
NCT03739814 Phase II Blinatumomab + inotuzumab ozogamicin Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Recruiting
NCT03740334 Phase I Dexamethasone + Ribociclib Dexamethasone + Everolimus + Ribociclib Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL Recruiting
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting
NCT03808610 Phase Ib/II Cyclophosphamide + Dexamethasone + Venetoclax + Vincristine Cyclophosphamide + Dexamethasone + Rituximab + Venetoclax + Vincristine Cytarabine + Methotrexate + Venetoclax Cytarabine + Methotrexate + Rituximab + Venetoclax Nelarabine + Pegaspargase Prednisone + Venetoclax + Vincristine Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Recruiting
NCT03826992 Phase I CPX-351 + Venetoclax Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Recruiting
NCT03851081 Phase Ib/II inotuzumab ozogamicin + Vincristine sulfate liposome Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Not yet recruiting
NCT03856216 Phase II Methotrexate Filgrastim + Methotrexate + Rituximab Rituximab Bendamustine + Fludarabine + inotuzumab ozogamicin + Tacrolimus Filgrastim + Methotrexate inotuzumab ozogamicin Fludarabine + inotuzumab ozogamicin + Melphalan + Tacrolimus anti-thymocyte globulin Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplant Not yet recruiting
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Recruiting